National
Baldwin sees hope in 112th Congress
LGBT Equality Caucus meeting set for March 16
Rep. Tammy Baldwin (D-Wisc.) (Blade photo by Michael Key)
Rep. Tammy Baldwin (D-Wisc.) maintained this week that pro-LGBT legislation could see progress in the Democratic-controlled Senate during the 112th Congress as prospects of movement are unlikely in the Republican-controlled House.
In an interview with the Washington Blade, the only out lesbian in Congress said she sees room for progress on pro-LGBT bills in the Senate, where Democrats retained control following the mid-term elections.
“There’s still a prospect with a Democratically controlled Senate that bills could progress through committee and maybe even come to the floor, depending on the circumstances,” Baldwin said.
Baldwin said determining which pro-LGBT legislation would have a shot of passing the Senate is hard to say, but cited one bill that she previously sponsored that would extend health and pension benefits to partners of LGBT federal employees.
“I think the Domestic Partnerships Benefits [& Obligations Act] could be one that might advance,” Baldwin said. “Obviously, they still have their 60-vote rule for advancing certain measures to the floor. But could something come up as an amendment to a bill that’s very likely to pass? Well, that remains to be seen.”
While Baldwin said the Senate could lead the way for pro-LGBT legislation in the 112th Congress, she said lawmakers who would introduce the bills have yet to determine the schedule for doing so.
“We’re having some initial discussions about timing, but as the bills have different co-sponsors, I think that different folks have their own timeline,” she said.
Even for her own Domestic Partnership Benefits & Obligations Act, Baldwin said the timing for introduction of her bill remains uncertain as House and Senate sponsors work on hammering out identical legislation.
“We just want to make sure that we’re on the same page with the Senate sponsors and introduce the bill in the same [form],” Baldwin said.
Baldwin also commended President Obama for his recent declaration that the Defense of Marriage Act is unconstitutional and his decision to no longer defend the statute in court.
The Wisconsin lawmaker called the move a significant step toward DOMA’s “ultimate demise” and said it would bolster efforts to legislatively repeal the law. Rep. Jerrold Nadler (D-N.Y.) and Sen. Dianne Feinstein (D-Calif.) have announced they plan to introduce repeal legislation in the 112th Congress.
“In terms of the advancement of Congressman Nadler’s bill on repealing the Defense of Marriage Act, I expect that the president’s announcement and the administration’s decision will give it a boost and renewed attention,” Baldwin said. “Obviously, we should be working to repeal statutory measures that aren’t constitutional. I’m hoping that that will enable us to gather more co-sponsors than we’ve had in the past, and to draw attention to the topic of why it’s so necessary that we repeal this.”
Still, Baldwin expressed skepticism about the prospects of advancing DOMA repeal legislation to passage in the Republican-controlled House. Speaker John Boehner (R-Ohio) has convened a panel to direct House counsel to defend DOMA in court now that the Obama administration is no longer willing to defend it.
Despite Republican control of the House, Baldwin expressed continued optimism about the strength of the LGBT Equality Caucus, which she co-chairs along with the other three openly gay members of Congress, and said the group is only three lawmakers short of the membership it had in the 111th Congress before Democrats lost 63 seats in the chamber.
“That’s encouraging,” she said. “Even though we had these sweeping changes in House membership, we still have a very rock-solid core of people who are supporting equality.”
Baldwin said she expects the LGBT Equality Caucus to hold public events during the 112th Congress to highlight pro-LGBT legislation and discuss the members’ commitment to passing the bills.
One such meeting is already scheduled for March 16, when the caucus will host its first business meeting to honor its new chairs and vice chairs. Baldwin said the meeting will be open to the public.
Rep. Ileana Ros-Lehtinen (R-Fla.) — known as perhaps the most pro-LGBT House Republican — is the only GOP member of the LGBT Equality Caucus, but Baldwin said she’s courting other Republicans to sign on to the group now that they have control of the House.
“I’ve made it a personal goal during the next Congress to try to enroll a greater number of Republicans to our ranks,” Baldwin said. “We certainly know that there are some in the Republican caucus who do not wish it to remain the party of discrimination and hope that LGBT equality can become a bipartisan issue in the future.”
Among the GOP lawmakers that Baldwin said she may solicit to join the LGBT Equality Caucus is Rep. Judy Biggert (R-Ill.), who voted for an amendment to repeal “Don’t Ask, Don’t Tell” in May even before the Pentagon report was released.
Also on Baldwin’s list is Rep. Mary Bono Mack (R-Calif.), who has cast votes for hate crimes protection legislation, a version of the Employment Non-Discrimination Act and repeal of “Don’t Ask, Don’t Tell” as well as votes against a U.S. constitutional amendment banning same-sex marriage.
Although Baldwin said she believes the prospects for sending legislation to President Obama’s desk are slim, she said she expects all 33 bills identified as pro-LGBT legislation from the previous Congress to make an appearance again.
“I certainly anticipate that all of the pro-LGBT equality legislation that was introduced in the last Congress will be reintroduced in this Congress with a focus on those bills to educate our colleagues and to enlist larger numbers of supporters for that legislation even if we anticipate that the Republican leadership will not allow those bills to advance,” Baldwin said.
Baldwin also said omnibus legislation that would encompass all the pro-LGBT measures from the previous Congress into one bill could be a way to highlight their importance. Rep. David Cicilline (D-R.I.), the newest openly gay member of Congress, has said he wants to explore the possibility of introducing such legislation.
“I think that pointing out that discrimination still exists in many different arenas is a powerful and important point to keep on raising, and you can do so with legislation, you can do so with other means,” Baldwin said.
Still, Baldwin said she expects members of Congress who introduced the individual pro-LGBT bills to want to introduce them again and said omnibus legislation would work to complement those efforts.
“Any such omnibus bill would be in addition to a complement to the wonderful legislation that so many pro-equality colleagues have introduced,” Baldwin said.
Of all the pro-LGBT legislation that would be introduced in the 112th Congress, Baldwin expressed the greatest optimism about legislation that would eliminate the federal tax on employer-provided health benefits for same-sex partners. In the previous Congress, the legislation was known as the Tax Equity for Health Plan Beneficiaries Act.
Baldwin said work that gay GOP groups are doing to promote the legislation may give the bill “a slim chance.”
“I have been pleased to see both GOProud and Log Cabin Republicans make these tax equity issues a high priority,” Baldwin said. “Obviously, those organizations have some influence that we only hope increases over time. But, I think, probably if there were one legislative issue that there were rosier prospects for, that might be it.”
One possible vehicle for a measure that may see movement in the 112th Congress is reauthorization of the Elementary & Secondary Education Act. Gay rights supporters have been hoping this measure could pass with anti-bullying safeguards for LGBT students even with Republican control of the House.
Standalone legislation that would have addressed this issue was known as the Student Non-Discrimination Act and the Safe Schools Improvement Act in the 111th Congress.
Still, Baldwin expressed reservations about whether Republicans would agree to such a provision and said she has been discouraged by talk against anti-bullying efforts among her GOP colleagues.
“I have heard rhetoric from some of my Republican colleagues on the issue of anti-gay bullying that has disappointed me profoundly,” Baldwin said. “I would expect that if the Senate could include some language on anti-bullying measures, there would be some prospect to reach out to more reasonable-minded Republicans, but I certainly anticipate that there would be opposition.”
Additionally, talk in the Senate about restarting efforts to pass comprehensive immigration reform have given LGBT advocates hope that such legislation might include a provision to allow gay Americans to sponsor to sponsor their foreign same-sex partners for residency.
In the previous Congress, standalone legislation that would achieve such a goal was known as the Uniting American Families Act.
But Baldwin said she hasn’t yet gotten “a good read” on the prospects of passing comprehensive immigration reform at this stage in the 112th Congress — with or without the UAFA language.
“I know when the president mentioned it in his State of the Union address, I certainly saw some of my Republican colleagues either leap to their feet or express optimism about another attempt at passing comprehensive immigration reform,” Baldwin said. “But I would say that as we started our session, things have been quite divisive and whether this is the two-year term in which we can get it done or not is a big question mark to me.”
While generally pessimistic about the chances of passing pro-LGBT legislation this Congress, Baldwin also dismissed chances that anti-gay bills could make it into law.
The lawmaker said the Democratic-controlled Senate should be able to block the passage of anti-gay bills that pass the House — such as measures to repeal same-sex marriage in D.C. or thwart “Don’t Ask, Don’t Tell” repeal — from making it to the president’s desk.
“We do know that at the federal level, we still have divided government,” Baldwin said. “While it would be a sad day for the representatives of the People’s House to pass any of these specific measures, we do know that their likelihood of being considered or embraced by the U.S. Senate is slim, and we also know that the president can exercise his veto if anything were to get to his desk.”
Federal Government
Holiday week brings setbacks for Trump-Vance trans agenda
Federal courts begin to deliver end-of-year responses to lawsuits involving federal transgender healthcare policy.
While many Americans took the week of Christmas to rest and relax, LGBTQ politics in the U.S. continued to shift. This week’s short recap of federal updates highlights two major blows to the Trump-Vance administration’s efforts to restrict gender-affirming care for minors.
19 states sue RFK Jr. to end gender-affirming care ban
New York Attorney General Letitia James announced on Tuesday that the NYAG’s office, along with 18 other states (and the District of Columbia), filed a lawsuit to stop U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. from restricting gender-affirming care for minors.
In the press release, Attorney General James stressed that the push by the Trump-Vance administration’s crusade against the transgender community — specifically transgender youth — is a “clear overreach by the federal government” and relies on conservative and medically unvalidated practices to “punish providers who adhere to well-established, evidence-based care” that support gender-affirming care.
“At the core of this so-called declaration are real people: young people who need care, parents trying to support their children, and doctors who are simply following the best medical evidence available,” said Attorney General James. “Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices. My office will always stand up for New Yorkers’ health, dignity, and right to make medical decisions free from intimidation.”
The lawsuit is a direct response to HHS’ Dec. 18 announcement that it will pursue regulatory changes that would make gender-affirming health care for transgender children more difficult, if not impossible, to access. It would also restrict federal funding for any hospital that does not comply with the directive. KFF, an independent source for health policy research, polling, and journalism, found that in 2023 federal funding covered nearly 45% of total spending on hospital care in the U.S.
The HHS directive stems directly from President Donald Trump’s Jan. 28 Executive Order, Protecting Children From Chemical and Surgical Mutilation, which formally establishes U.S. opposition to gender-affirming care and pledges to end federal funding for such treatments.
The American Medical Association, the nation’s largest and most influential physician organization, has repeatedly opposed measures like the one pushed by President Trump’s administration that restrict access to trans health care.
“The AMA supports public and private health insurance coverage for treatment of gender dysphoria and opposes the denial of health insurance based on sexual orientation or gender identity,” a statement on the AMA’s website reads. “Improving access to gender-affirming care is an important means of improving health outcomes for the transgender population.”
The lawsuit also names Oregon, Washington, California, Colorado, Connecticut, Delaware, the District of Columbia, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Pennsylvania, Rhode Island, Vermont, and Wisconsin as having joined New York in the push against restricting gender-affirming care.
At the HHS news conference last Thursday, Jim O’Neill, deputy secretary of the department, asserted, “Men are men. Men can never become women. Women are women. Women can never become men.”
DOJ stopped from gaining health care records of trans youth
U.S. District Judge Cathy Bissoon blocked an attempt by the Department of Justice (DOJ) to gain “personally identifiable information about those minor transgender patients” from the University of Pittsburgh Medical Center (UPMC), saying the DOJ’s efforts “fly in the face of the Supreme Court.”
Journalist Chris Geidner originally reported the news on Dec. 25, highlighting that the Western District of Pennsylvania judge’s decision is a major blow to the Trump-Vance administration’s agenda to curtail transgender rights.
“[T]his Court joins the others in finding that the government’s demand for deeply private and personal patient information carries more than a whiff of ill intent,” Bissoon wrote in her ruling. “This is apparent from its rhetoric.”
Bissoon cited the DOJ’s “incendiary characterization” of trans youth care on the DOJ website as proof, which calls the practice politically motivated rather than medically sound and seeks to “…mutilate children in the service of a warped ideology.” This is despite the fact that a majority of gender-affirming care has nothing to do with surgery.
In United States v. Skrmetti, the Supreme Court ruled along party lines that states — namely Tennessee — have the right to pass legislation that can prohibit certain medical treatments for transgender minors, saying the law is not subject to heightened scrutiny under the Equal Protection Clause of the Fourteenth Amendment because it does not involve suspect categories like race, national origin, alienage, and religion, which would require the government to show the law serves a compelling interest and is narrowly tailored, sending decision-making power back to the states.
“The government cannot pick and choose the aspects of Skrmetti to honor, and which to ignore,” Judge Bissoon added.
The government argued unsuccessfully that the parents of the children whose records would have been made available to the DOJ “lacked standing” because the subpoena was directed at UPMC and that they did not respond in a timely manner. Bissoon rejected the timeliness argument in particular as “disingenuous.”
Bissoon, who was nominated to the bench by then-President Obama, is at least the fourth judge to reject the DOJ’s attempted intrusion into the health care of trans youth according to Geidner.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
Looking back at the 10 biggest A&E stories of 2025
Kazakh president signs anti-LGBTQ propaganda bill
Top 10 LGBTQ local news stories of 2025
The 25 greatest queer movies of the 21st century so far
How to cope when a partner gives you the silent treatment
Your guide to D.C.’s queer New Year’s Eve parties
Holiday week brings setbacks for Trump-Vance trans agenda
Out actor talks lead role in ‘Fiddler on the Roof’
This gay author sees dead people
